Aggression in Borderline Personality Disorder

Psychiatric Quarterly

Volumn 81, Issue 3, 2010, Pages 239-251

  Latalova K ^a   Prasko J ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Aggression; Anticonvulsants; Antipsychotics; Borderline Personality Disorder; Cognitive behavioral therapy; Dialectical behavioral therapy; Group therapy; Pharmacotherapy; Psychotherapy

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; NALTREXONE; OLANZAPINE; OMEGA 3 FATTY ACID; PHENELZINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGGRESSION; BIPOLAR DISORDER; BORDERLINE STATE; CLINICAL TRIAL; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; COGNITIVE THERAPY; COMORBIDITY; DRUG DOSE REDUCTION; GROUP THERAPY; HUMAN; IMPULSIVENESS; MENTAL INSTABILITY; MONOTHERAPY; PSYCHODYNAMICS; PSYCHOPATHY; REVIEW; VIOLENCE;

EID: 78149360781     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-010-9133-3     Document Type: Review

References (68)

1. Oquendo MA, Mann JJ: The biology of impulsivity and suicidality. Psychiatric Clinics of North America 23:11-25, 2000.
2. Moyer KE: The Psychobiology of Aggression. New York, Harper & Row Publishers, 1976.
3. Citrome L, Volavka J: Treatment of Violent Behavior. In: Tasman A, Kay J, Lieberman JA (Eds) Psychiatry, 2 edn. Chichester, John Wiley & Sons Ltd, 2003.
4. Soloff PH, Meltzer CC, Becker C, et al.: Impulsivity and prefrontal hypometabolism in borderline personality disorder. Psychiatry Research: Neuroimaging Section 123:153-163, 2003.
5. Coccaro EF, Harvey PD, Kupsaw-Lawrence E, et al.: Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. Journal of Neuropsychiatry and Clinical Neurosciences 3: S44-S51, 1991.
6. Arntz A, van den HM, Cornelis J, et al.: Reliability and validity of the borderline personality disorder severity index. Journal of Personality Disorders 17:45-59, 2003.
7. Buss AH, Durkee A: An inventory for assessing different kinds of hostility. Journal of Consulting Psychology 21:343-349, 1957.
8. Schwenkenmezger P, Hodapp V, Spielberger CD: The State-Trait Anger Expression Inventory. Goettingen, Huber, 1992.
9. Buss AH, Perry M: The aggression questionnaire. Journal of Personality and Social Psychology 63:452-459, 1992.
10. Swanson JW, Holzer CE, Ganju VK, et al.: Violence and psychiatric disorder in the community: evidence from the epidemiologic catchment area surveys. Hospital and Community Psychiatry 41:761-770, 1990.
11. Pulay AJ, Dawson DA, Hasin DS, et al.: Violent behavior and DSM-IV psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions. Journal of Clinical Psychiatry e1-e11, 2007.
12. Fazel S, Gulati G, Linsell L, et al.: Schizophrenia and violence: systematic review and meta-analysis. PLoS Medicine 6: e1000120, 2009.
13. Fountoulakis KN, Leucht S, Kaprinis GS: Personality disorders and violence. Current Opinion in Psychiatry 21:84-92, 2008.
14. Grant BF, Chou SP, Goldstein RB, et al.: Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the wave 2 national epidemiologic survey on alcohol and related conditions. Journal of Clinical Psychiatry 69:533-545, 2008.
15. Zanarini MC, Frankenburg FR, Reich DB, et al.: Violence in the lives of adult borderline patients. Journal of Nervous and Mental Disease 187:65-71, 1999.
16. Goodman M, New A: Impulsive aggression in borderline personality disorder. Current Psychiatry Reports 2:56-61, 2000.
17. de Barros DM, de Padua SA: Association between personality disorder and violent behavior pattern. Forensic Science International 179:19-22, 2008.
18. Nickel MK, Nickel C, Mitterlehner FO, et al.: Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. Journal of Clinical Psychiatry 65:1515-1519, 2004.
19. Raine A: Features of borderline personality and violence. Journal of Clinical Psychology 49:277-281, 1993.
20. Swartz MS, Swanson JW, Hiday VA, et al.: Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. American Journal of Psychiatry 155:226-231, 1998.
21. Latalova K: Bipolar disorder and aggression. International Journal of Clinical Practice 63:889-899, 2009.
22. Coid J, Yang M, Roberts A, et al.: Violence and psychiatric morbidity in the national household population of Britain: public health implications. British Journal of Psychiatry 189:12-19, 2006. (Pubitemid 44023324)
23. Howard RC, Huband N, Duggan C, et al.: Exploring the link between personality disorder and criminality in a community sample. Journal of Personality Disorders 22:589-603, 2008.
24. Elbogen EB, Johnson SC: The intricate link between violence and mental disorder: results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry 66:152-161, 2009.
25. Soloff PH, George A, Nathan RS, et al.: Progress in pharmacotherapy of borderline disorders. A doubleblind study of amitriptyline, haloperidol, and placebo. Archives of General Psychiatry 43:691-697, 1986.
26. Soloff PH, Cornelius J, George A, et al.: Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry 50:377-385, 1993. (Pubitemid 23143127)
27. Simpson EB, Yen S, Costello E, et al.: Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 65:379-385, 2004.
28. Rinne T, van den BW, Wouters L, et al.: SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry 159:2048-2054, 2002.
29. Nickel MK, Muehlbacher M, Nickel C, et al.: Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 163:833-838, 2006. (Pubitemid 44464531)
30. Soler J, Pascual JC, Campins J, et al.: Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry 162:1221-1224, 2005.
31. Pascual JC, Oller S, Soler J, et al.: Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. Journal of Clinical Psychiatry 65:1281-1282, 2004.
32. Bellino S, Paradiso E, Bogetto F: Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. Journal of Clinical Psychiatry 67:1042-1046, 2006.
33. Perrella C, Carrus D, Costa E, et al.: Quetiapine for the treatment of borderline personality disorder; an open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 31:158-163, 2007.
34. Van den Eynde F, Senturk V, Naudts K, et al.: Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. Journal of Clinical Psychopharmacology 28:147-155, 2008.
35. Chengappa KN, Ebeling T, Kang JS, et al.: Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Journal of Clinical Psychiatry 60:477-484, 1999.
36. Rocca P, Marchiaro L, Cocuzza E, et al.: Treatment of borderline personality disorder with risperidone. Journal of Clinical Psychiatry 63:241-244, 2002.
37. Tritt K, Nickel C, Lahmann C, et al.: Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology 19:287-291, 2005.
38. Nickel MK, Nickel C, Kaplan P, et al.: Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biological Psychiatry 57:495-499, 2005.
39. Frankenburg FR, Zanarini MC: Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry 63:442-446, 2002.
40. Simeon D, Baker B, Chaplin W, et al.: An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectrums 12:439-443, 2007.
41. Zanarini MC, Frankenburg FR: Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. American Journal of Psychiatry 160:167-169, 2003.
42. Links PS, Heslegrave R, Villella J: Psychopharmacological management of personality disorders: an outcome focused model. In: Silk KR (Ed) Biology of personality disorders. Washington, DC, American Psychiatric Press, pp. 93-127, 1998.
43. Soloff PH: Algorithm for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective and impulsive-behavioral dysregulation. Bulletin of the Menninger Clinic 62:195-214, 1998.
44. Stevenson J, Meares R: An outcome study of psychotherapy for patients with borderline personality disorder. American Journal of Psychiatry 149:358-362, 1992.
45. Meares R, Stevenson J, Comerford A: Psychotherapy with borderline patients, I: a comparison between treated and untreated cohorts. Australian and New Zealand Journal of Psychiatry 33:467-472, 1999.
46. Clarkin JF, Foelsch P, Levy KN et al.: The development of a psychodynamic treatment for patients with borderline personality disorder: a preliminary study of behavioural change. The Journal of Personality Disorders 15:487-495, 2001.
47. Bateman A, Fonagy P: The effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. American Journal of Psychiatry 156:1563-1569, 1999.
48. Bateman A, Fonagy P: Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-months follow up. American Journal of Psychiatry 158:36-42, 2001.
49. Beck AT, Freeman AM: Cognitive therapy of personality disorders. New York, Guilford, 1990.
50. Davidson KA, Tyrer P: Cognitive therapy for antisocial and borderline personality disorders: single case study series. British Journal of Clinical Psychology 35:413-429, 1996.
51. Tyrer P, Tom B, Byford S, et al.: Differential effects of manual assisted cognitive behaviour therapy in the treatment of recurrent deliberate self-harm and personality disturbance: the POPMACT study. The Journal of Personality Disorders 4:161-172, 2004.
52. Davidson K, Norrie JA, Tyrer P: The effectiveness of cognitive behavioral therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. The Journal of Personality Disorders 20:450-465, 2006.
53. Linehan MM: Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York, Guilford, 1993.
54. Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL: Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry 48:1060-1064, 1991.
55. Linehan MM, Tutek DA, Heard HL, Armstrong HE: Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. American Journal of Psychiatry 151:1771-1776, 1994.
56. Linehan MM, Schmidt H III, Dimeff LA, Craft JC, Kanter J, Comtois KA: Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. American Journal on Addictions 8:279-292, 1999.
57. Linehan MM, Heard HL, Armstrong HE: Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Archives of General Psychiatry 50:971-974, 1993.
58. Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N: Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Archives of General Psychiatry. 63:757-766, 2006.
59. Binks CA, Fenton M, McCarthy L et al.: Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews 1: CD005653, 2006.
60. Nose M, Cipriani A, Biancosino B et al.: Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. International Clinical Psychopharmacology 21:345-353, 2006.
61. Herpertz SC, Zanarini M, Schulz CS et al.: World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World Journal of Biological Psychiatry 8:212-244, 2007.
62. Soloff PH, George A, Nathan RS, et al.: Paradoxical effects of amitriptyline on borderline patients. American Journal of Psychiatry 143:1603-1605, 1986.
63. Soloff PH, George A, Nathan RS, et al.: Behavioral dyscontrol in borderline patients treated with amitriptyline. Psychopharmacology Bulletin 23:177-181, 1987.
64. Linehan MM, McDavid JD, Brown MZ, et al.: Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebocontrolled pilot study. Journal of Clinical Psychiatry 69:999-1005, 2008.
65. Pascual JC, Soler J, Puigdemont D, et al.: Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. Journal of Clinical Psychiatry 69:603-608, 2008.
66. Lipman RS, Covi L, Shapiro AK: The Hopkins symptom checklist (HSCL)-factors derived from the HSCL-90. Journal of Affective Disorders 1:9-24, 1979.
67. Teicher MH, Glod CA, Aaronson ST, et al.: Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacology Bulletin 25:535-549, 1989.
68. Hollander E, Allen A, Lopez RP, et al.: A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry 62:199-203, 2001.